+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice

Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice

Herz 37(4): 384-392

The standardized and constant fixed-dose rate, no necessity for a close and regular blood monitoring as well as the small number of interactions with other drugs and daily food make therapy with the new oral anticoagulants dabigatran and rivaroxaban and in future presumably apixaban much easier and more feasible than the standard therapy with vitamin K antagonists (VKA). In summary the trials focusing on patients with non-valvular atrial fibrillation show that the new substances are at least non-inferior or even coequal to the well-known VKAs regarding prevention of thromboembolism. In addition the risk of fatal and especially intracranial hemorrhage can be considered even lower. Furthermore, the trials indicate a trend in reduction of death from any cause in treating these patients with the new drugs. There was no inferiority or even superiority in patient-outcome in extended prevention of venous thrombosis and pulmonary embolism after knee or hip arthroplasty when treating patients with the new substances by oral administration versus subcutaneous administration of low molecular weight heparin. Comparable results were demonstrated in the therapy of patients with acute deep vein thrombosis compared with the standard therapy of low molecular weight heparin and VKAs while there was a similar safety profile. Concerning the specific treatment of coronary heart disease and a combined antiplatelet therapy, profound data are still missing. The lack of specific antidotes the as yet limited experience with these substances over a longer period of time and last but not least the emerging costs have inhibited a broad use of these new agents up until now.

(PDF emailed within 0-6 h: $19.90)

Accession: 055614159

Download citation: RISBibTeXText

PMID: 22565860

DOI: 10.1007/s00059-012-3619-8

Related references

Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. International Journal of Clinical Practice 64(7): 835-838, 2011

Safety and efficacy of novel oral anticoagulants: a comparison to vitamin K antagonists. Cardiovascular & Hematological Agents in Medicinal Chemistry 12(1): 9-13, 2015

Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). European Journal of Clinical Pharmacology 71(10): 1283-1284, 2016

Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension 24(2): 183-192, 2015

Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. Seminars in Hematology 51(2): 102-111, 2014

Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Seminars in Thrombosis and Hemostasis 41(2): 178-187, 2015

Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on PharmacoTherapy 17(15): 2033-2047, 2016

New oral anticoagulants: better than vitamin K antagonists?. Der Internist 51(12): 1571-1581, 2011

Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. Journal of the American Society of Nephrology 25(3): 431-442, 2014

New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clinical Pharmacokinetics 52(2): 69-82, 2013

Geographic variations in the quality of oral anticoagulation with vitamin k antagonists in the era of new anticoagulants. Journal of the American Heart Association 2(1): E000088-E000088, 2013

Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding. Annals of Internal Medicine 161(6): Jc10-Jc10, 2014

Vitamin K antagonists, direct oral anticoagulants, and the rationale for reversal agents. American Journal of Health-System Pharmacy 73(10 Suppl 2): S3-S4, 2016

New oral anticoagulants versus vitamin K antagonists in countries with good INR control. Netherlands Journal of Medicine 71(4): 168-169, 2014

Are New Oral Anticoagulants Safer Than Vitamin K Antagonists in the Treatment of Venous Thromboembolism?. Annals of Emergency Medicine 67(4): 455-457, 2016